[Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors].
We have found that intravenous administration of cannabinoid receptor (CB) agonist HU-210 (0.05 mg/kg), increases cardiac resistance against arrhythmogenic effect of epinephrine, aconitine, coronary artery occlusion and reperfusion in rats. Pretreatment with CB2-receptor antagonist, SR144528 (1 mg/kg), completely abolished the antiarrhythmic effect of HU-210. However this effect of HU-210 was not attenuated by pretreatment with CB1-receptor antagonist, SR141716A (3 mg/kg). We also found that HU-210 (0.05 mg/kg) decreased the relationship between infarction size and area of ischemia. It is concluded that CB2 receptor stimulation promotes an increase in the cardiac resistance against arrhythmogenic influences and probably increases myocardial tolerance of both ischemic and reperfusion damages in rats.
Krylatov
A V
AV
Tomsk Institute of Cardiology, 111 Kievskaya St., 634050 Tomsk, Russia.
Bernatskaia
N A
NA
Maslov
L N
LN
Pertwee
R G
RG
Mechoulam
R
R
Stefano
G B
GB
Sharaevskiĭ
M A
MA
Sal'nikova
O M
OM
D000157:Aconitine; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D001157:Arterial Occlusive Diseases / Q000150:complications; D001892:Camphanes / Q000494:pharmacology; D002186:Cannabinoids / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000150:complications; D013759:Dronabinol / Q000031:analogs & derivatives / Q000494:pharmacology; D004837:Epinephrine; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists* / Q000037:antagonists & inhibitors; D000077285:Rimonabant
D000889:Anti-Arrhythmia Agents; D001892:Camphanes; D002186:Cannabinoids; C469526:Cnr2 protein, rat; D010880:Piperidines; D011720:Pyrazoles; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C110630:SR 144528; D013759:Dronabinol; C062018:HU 211; D000077285:Rimonabant; D000157:Aconitine; D004837:Epinephrine